Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.
NovoCure's current Total Payout Ratio is 0.04.
NovoCure Total Payout Ratio Historical Data
The historical data trend for NovoCure's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
NovoCure Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Total Payout Ratio |
|
|
|
|
|
0.03 |
0.03 |
0.34 |
-0.17 |
0.08 |
|
NovoCure Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Total Payout Ratio |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
0.16 |
- |
- |
- |
Competitive Comparison
For the Medical Instruments & Supplies subindustry, NovoCure's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Total Payout Ratio Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's Total Payout Ratio falls into.
NovoCure Total Payout Ratio Calculation
Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.
NovoCure's Total Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as
NovoCure's Total Payout Ratio for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Business Description
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Executives
| Weinberg Uri |
officer: Chief Science Officer |
NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
| Groenhuysen Wilhelmus Cm |
officer: Chief Operating Officer |
C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654 |
| Danziger Asaf |
director, officer: Chief Executive Officer |
5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302 |
| Leung Gabriel |
director |
C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960 |
| Shah Pritesh |
officer: Chief Commercial Officer |
C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
| Leonard Frank X |
officer: Chief Development Officer |
20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
| Cordova Ashley |
officer: Chief Financial Officer |
20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
| Madden Martin J. |
director |
C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043 |
| Benaim Ely |
officer: Chief Medical Officer |
C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 |
| Doyle William F |
director, officer: Executive Chairman |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Ambrogi Michael J. |
officer: Chief Operating Officer |
195 COMMERCE WAY PORTSMOUTH NH 03801 |
| Longsworth Todd Christopher |
officer: General Counsel |
NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
| Hilleman Jeryl L |
director |
C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025 |
| Mccoy Sherilyn S |
director |
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
| Hung David |
director |
C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
NovoCure Headlines
By Seekingalpha 2021-07-30
By tipranks.com 2022-03-05
By Seekingalpha 2022-02-24
By Seekingalpha 2021-11-30
By Seekingalpha 2021-09-13
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
3.79(4.73%) Volume: 599,319 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:NVCR has been successfully added to your 